Chromatin modification-related protein MEAF6 (MEAF6)

Chromatin modification-related protein MEAF6 (abbreviation: MEAF6) is a nuclear protein crucial for **transcriptional activation** via participation as a subunit in several multisubunit **histone acetyltransferase complexes** (including NuA4, HBO1, and MOZ/MORF complexes)[1][2][4][6]. These complexes modulate chromatin structure by acetylating histones H3, H4, and H2A, contributing to the regulation of gene expression[2][4][6]. MEAF6 is important in the **assembly of KAT7 complexes** and is essential for cell proliferation[7]. Alternative splicing results in multiple transcript variants, which have distinct functional roles, with specific splice forms (e.g., MEAF6-1) implicated in tumor progression in advanced prostate cancer[1]. MEAF6 is primarily of interest in oncology due to its involvement in gene fusions (e.g., MEAF6-PHF1), which are recurrent molecular events in certain sarcomas such as ossifying fibromyxoid tumors and endometrial stromal sarcoma[1]. These events disrupt normal chromatin regulation and serve both as drivers of tumorigenesis and as diagnostic biomarkers. MEAF6 expression is regulated by transcription factors and microRNAs and exhibits cell- and tissue-type specific distribution[1][2]. Direct drug modulation of MEAF6 is not established, but its role in chromatin remodeling and epigenetic mechanisms makes it a relevant target for potential future therapies and molecular diagnostics[2][4][6].

Other names

MYST/Esa1-associated factor 6MEAF6C1orf149CENP-28EAF6NY-SAR-91Protein EAF6 homologhEAF6FLJ11730Esa1-associated factor 6 homologSarcoma antigen NY-SAR-91centromere protein 28

Potential mechanisms rely on inhibition or modulation of histone acetyltransferases or complexes containing MEAF6. Specific MEAF6-targeting mechanisms of action are not documented in the selected literature; indirect mechanisms may be inferred via inhibition of associated histone acetyltransferase complexes